Target intelligence / Profile preview

Tripartite motif-containing protein 37 (TRIM37)

Target
TRIM37
Molecular classification
E3 ubiquitin ligase, Enzyme, RING-B-box-coiled-coil (TRIM) family, Other
01

Overview

Tripartite motif-containing protein 37 (TRIM37) is an E3 ubiquitin ligase and a member of the TRIM family of proteins, characterized by RING, B-box, and coiled-coil domains[1][5]. TRIM37 catalyzes ubiquitination of specific substrate proteins, including histone H2A, modulating transcriptional repression of tumor suppressor genes, and regulates protein assemblies at centrosomes and spindle poles to ensure proper cell division and chromosomal segregation[1][2][3][4]. Germline mutations result in Mulibrey nanism, a multisystem developmental disorder associated with high tumor risk, while somatic copy number gain or overexpression of TRIM37 is linked to aggressive forms of breast cancer and neuroblastoma[1][3][4]. Elevated TRIM37 sensitizes cells to centrinone—a PLK4 inhibitor—providing a potential therapeutic vulnerability in cancer[3]. Loss or dysregulation of this protein is associated with centrosomal abnormalities, genome instability, and altered transcriptional landscapes promoting oncogenesis[1][2][3][4][5].

Other names
E3 ubiquitin-protein ligase TRIM37KIAA0898MULPOB1TEF3Mulibrey nanism proteinRING-type E3 ubiquitin transferase TRIM37RING-B-box-coiled-coil protein
02

Mechanism of action

Centrinone: inhibits PLK4, targeting cells bearing excess TRIM37 and with aberrant centrosome numbers[3]

03

Biological functions

Ubiquitination of target proteins (including histone H2A)Regulation of centrosome biology/centrosome assemblyControl of cell division (spindle pole formation)Regulation of chromatin structure/transcriptional repressionMaintenance of genome integrity
04

Disease associations

Cancer (notably breast cancer, neuroblastoma)Developmental disorder (Mulibrey nanism)Tumorigenesis/oncogenesis
05

Safety considerations

Risk of impaired organ growth and developmental abnormalities with loss-of-functionCancer risk with both loss (Mulibrey nanism) and gain (amplification in cancer) of function[1][3][4]
06

Interacting drugs

centrinone (PLK4 inhibitor; increased sensitivity in TRIM37-overexpressing cells)[3]
07

Biomarkers

TRIM37 copy number amplification (notably in breast cancer and neuroblastoma)[1][3]

Beyond the preview

Go deeper on Tripartite motif-containing protein 37 (TRIM37).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tripartite motif-containing protein 37 (TRIM37).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call